Due Diligence (5)

Challenge: A private equity investor was considering a transaction in a company supplying therapeutic proteins derived from biological sources for the treatment of numerous diseases in the...

Challenge: A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.

Challenge: A VC investor wished to make an investment in a California-based preclinical biotechnology company with a discovery platform and novel T cell therapies for cancer and other diseases....

Challenge: A UK-based VC wished to invest in a biotech spin-out focussed on the development of R&D tools using induced pluripotent stem cells (iPSCs) as organoids to mimic human tissues. These...

Challenge: Following a pre-due diligence exercise, an investment firm asked Alacrita to conduct a deeper due diligence on a biotech company's vaccine platform technology targeted towards infectious...

Challenge: A VC investor asked Alacrita to conduct due diligence on a clinical stage oncology therapeutic company developing a targeted inhibitor that works via the notch pathway. Priority...

Challenge: A government owned investment firm was considering an investment in a small biopharma company developing a therapeutic monoclonal antibody against a novel immuno-oncology target. Alacrita...

Challenge: A transatlantic life science venture capital fund was contemplating investing in advanced plasma product opportunities being developed by a biopharmaceutical company, and needed a reality...

Challenge: A major European venture capital investor needed to analyze the business plan of a novel point-of-care diagnostics company.

Challenge: An early-stage venture fund asked Alacrita to review the opportunity for reinvestment in a biotech developing a novel live biotherapeutic for the treatment of inflammatory bowel disorders...

Challenge: A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.

Challenge: A venture capital investor needed a reality check on a clinical stage cancer biologic prior to a proposed $10m investment with a very short deadline.